Mylan works with government, trade associations, healthcare providers, patient-advocacy groups and others to shape policies that help people across the nation enjoy better health.
Mylan has a decades-long track record of expanding people’s access to medicine, particularly by making more-affordable generic versions of brand name drugs – expertise we’re now bringing to biologics, insulins and other complex medicines.
Helped establish the generic industry’s first trade association
Helped give rise to legislation creating the modern generics industry
Helped modernize Medicare, including the introduction of a prescription-drug benefit
Led the way to ensure one quality standard for all medicines sold in the U.S.
In 1984, Generic drugs made up only 19% of prescriptions dispensed in the U.S.
In 2017, they made up 90% of prescriptions dispensed
The introduction of just 11 biosimilars in the U.S. could save the nation’s healthcare system $250 billion over 10 years.
Mylan has about 20 biosimilar and insulin analog products on the market around the world or in development.
of all people worldwide being treated for HIV/ AIDS depend on a Mylan antiretroviral product.
of Mylan’s active pharmaceutical ingredient manufacturing capacity is devoted to antiretrovirals.